Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis

Chad Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic

James Gideon, MD, PhD
Blanchard Valley Medical Associates, Findlay, OH

Address: Chad Deal, MD, Department of Rheumatic and Immunologic Disease, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Deal has indicated that he serves as a consultant for and is on the speaker’s bureau of Eli Lilly and Company.

Chad Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic

James Gideon, MD, PhD
Blanchard Valley Medical Associates, Findlay, OH

Address: Chad Deal, MD, Department of Rheumatic and Immunologic Disease, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Deal has indicated that he serves as a consultant for and is on the speaker’s bureau of Eli Lilly and Company.

Chad Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic

James Gideon, MD, PhD
Blanchard Valley Medical Associates, Findlay, OH

Address: Chad Deal, MD, Department of Rheumatic and Immunologic Disease, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Deal has indicated that he serves as a consultant for and is on the speaker’s bureau of Eli Lilly and Company.